Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids

被引：0

作者：

Talaulikar, Vikram Sinai ^{[1
]}

Manyonda, Isaac ^{[1
]}

机构：

[1] St Georges Hosp & Univ London, London SW17 0RE, England

来源：

WOMENS HEALTH | 2014年 / 10卷 / 06期

关键词：

fibroids; medical; myoma; SPRM; ulipristal acetate;

D O I：

10.2217/WHE.14.60

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Although it has been known for a long time that uterine fibroids respond to changes in sex steroid concentrations, it is the availability of selective progesterone receptor modulators such as ulipristal acetete that has provided the gynecologist with a novel option for medical management of uterine fibroids. Ulipristal acetate is presently licensed in Europe for use in women with symptomatic fibroids up to 3 months prior to surgery and has demonstrated good clinical efficacy and safety for this indication. Future trials will define the long-term safety of this drug and its role in medical management of uterine fibroids.

引用

页码：565 / 570

页数：6

共 50 条

[21] Long-term medical management of uterine fibroids with ulipristal acetate
Donnez, Jacques
Donnez, Olivier
Matule, Dace
Ahrendt, Hans-Joachim
Hudecek, Robert
Zatik, Janos
Kasilovskiene, Zaneta
Dumitrascu, Mihai Cristian
Fernandez, Herve
Barlow, David H.
Bouchard, Philippe
Fauser, Bart C. J. M.
Bestel, Elke
Loumaye, Ernest
FERTILITY AND STERILITY, 2016, 105 (01) : 165 - +
[22] Repeated-intermittent use of ulipristal acetate for the management of uterine fibroids: an Italian pharmacoeconomic evaluation
Maratea, Dario
MINERVA GINECOLOGICA, 2016, 68 (01): : 15 - 20
[23] Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy
Brun, Jean-Luc
Rajaonarison, Jose
Froeliger, Alizee
Monseau-Thiburce, Anne-Coline
Randriamboavonjy, Rado
Vogler, Andrej
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2018, 222 : 13 - 18
[24] Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital
Woodhead, Natalie
Pounds, Rachel
Irani, Shirin
Pradhan, Poonam
JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2018, 38 (06) : 813 - 817
[25] Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids
Middelkoop, Mei-An
de Lange, Maria E.
Clark, T. Justin
Mol, Ben Willem J.
Bet, Pierre M.
Huirne, Judith A. F.
Hehenkamp, Wouter J. K.
HUMAN REPRODUCTION, 2022, 37 (05) : 884 - 894
[26] Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis
Kalampokas, Theodoros
Kamath, Mohan
Boutas, Ioannis
Kalampokas, Emmanouil
GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 (02) : 91 - 96
[27] Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas
Gracia, Meritxell
Alcala, Marta
Ferreri, Janisse
Rius, Mariona
Ros, Cristina
Adela Saco, Maria
Angeles Martinez-Zamora, Maria
Carmona, Francisco
JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2018, 25 (07) : 1274 - 1280
[28] Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate
Yun, Bo Seong
Seong, Seok Ju
Jung, Yong Wook
Kim, Mi-La
Bae, Hyo Sook
Kim, Mi Kyoung
Shim, Sung Shin
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2018, 224 : 133 - 136
[29] ULIPRISTAL ACETATE FOR UTERINE FIBROID-RELATED SYMPTOMS
Puchar, A.
Luton, D.
Koskas, M.
DRUGS OF TODAY, 2015, 51 (11) : 661 - 667
[30] Endometrial Morphology After Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator, Ulipristal Acetate
Williams, Alistair R. W.
Bergeron, Christine
Barlow, David H.
Ferenczy, Alex
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2012, 31 (06) : 556 - 569

← 1 2 3 4 5 →